kymera therapeutics gilead

News

Gilead Sciences Signs $750M Deal For Cancer Drug

Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of a class of cancer drugs, the companies said on Wednesday. As part of the deal,

Seeking Alpha on MSN · 2d

Gilead and Kymera in pact to develop cancer drugs

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to develop and sell a band of cancer drugs. Under the deal, Kymera could receive up to $750M,

pharmaphorum · 2d

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

PharmExec2d

Gilead, Kymera Launch Collaboration on Novel Oral CDK2 Degraders for Solid Tumors

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Medical Dialogues2d

Gilead Sciences, Kymera Therapeutics ink pact to develop novel oral molecular glue CDK2 degraders

Gilead Sciences, Inc. and Kymera Therapeutics, Inc., have entered into an exclusive option and license agreement for ...

Morningstar3d

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Morningstar

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results